Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly ...
FRAMINGHAM, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results